UNSPSC 51386404: Balsalazide sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H13N3O6.2Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XL6BJI034, chemically known as benzoic acid, 5-((1e)-(4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt, dihydrate, but more generally known as balsalazide sodium, which bears US NIH Compound Identifier 6504526.

European Medicines Agency schedules balsalazide sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06092MIG. Most nations, for tariff purposes, schedule balsalazide sodium under HS 29270000. SMILES: C1CC(CCC1C(=O)NCCC(=O)[O-])/N=N/C2CCC(C(C2)C(=O)[O-])O.O.O.[NA+].[NA+].

UNSPSC 51386404 Balsalazide sodium is a Commodity code that captures pharmaceutical active pharmaceutical ingredients and finished-dose medications procured by state and local health agencies. However, the recent state and local opportunities posted under this code show minimal alignment with balsalazide itself — a drug used to treat ulcerative colitis — and instead reflect broader pharmaceutical procurement activity including naloxone, generic multi-source pharmaceuticals, and over-the-counter products. State and local issuers soliciting under this code range from county health departments and state health and human services commissions to cooperative purchasing alliances serving multiple states. The work being solicited includes direct product supply through authorized wholesalers, manufacturer-to-distributor agreements, and county-level procurement of specific pharmaceutical products with defined unit volumes and delivery schedules. Procurement mechanisms vary widely, from fixed competitive bids for defined annual quantities to requests for information gathering vendor capabilities for future program design.

The geographic spread includes Florida, Texas, and a multistate cooperative centered in Minnesota serving participating jurisdictions across multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026. The code shows recent activity but limited specific opportunities directly matching balsalazide procurement.